Alexion Pharmaceuticals Inc. Executive Vice President and CFO Paul Clancy will step down from the role after filing results for the third quarter, which closes at the end of September.
Chief Strategy and Business Officer Aradhana Sarin will step in as the new CFO while Clancy will serve as senior adviser through half of 2020.
"Over the last two years, [Paul] has played an invaluable role in our efforts to rebuild Alexion, refocus our corporate strategy and position the company for its next chapter," Alexion CEO Ludwig Hantson said in a Sept. 17 release.
Sarin has worked for Alexion, a Boston company developing treatments for rare diseases, since late 2017, and she oversaw nine business development deals in that time.
